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Abstract
Biliary disorders can lead to life‐threatening disease and are also a challenging
complication of liver transplantation. As there are limited treatment options, tissue
engineered bile ducts could be employed to replace or repair damaged bile ducts.
We explored how these constructs can be created by seeding hepatobiliary LGR5+
organoids onto tissue‐specific scaffold. For this, we decellularized discarded human
extrahepatic bile ducts (EBD) that we recellularized with organoids of different
origin, that is, liver biopsies, extrahepatic bile duct biopsies, and bile samples. Here,
we demonstrate efficient decellularization of EBD tissue. Recellularization of the
EBD extracellular matrix (ECM) with the organoids of extrahepatic origin (EBD
tissue and bile derived organoids) showed more profound repopulation of the ductal
ECM when compared with liver tissue (intrahepatic bile duct) derived organoids. The
bile duct constructs that were repopulated with extrahepatic organoids expressed
mature cholangiocyte‐markers and had increased electrical resistance, indicating
restoration of the barrier function. Therefore, the organoids of extrahepatic sources
are identified to be the optimal candidate for the development of personalized tissue
engineered EBD constructs.
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1 | INTRODUCTION
Biliary complications, such as bile leaks and anastomotic strictures,
occurring after donation after circulatory death (DCD) liver trans-
plantation (LT) are common and a major cause of posttransplant
complications and morbidity (Hessheimer et al., 2016; de Vries et al.,
2018). In DCD LT, the biliary epithelial lining of the extrahepatic bile
ducts (EBD) is more prone to damage, due to the prolonged warm
ischemia period in the donor. This results in a higher incidence of
ischemia type biliary lesions, which leads to more diffuse non-
anastomotic biliary strictures, when compared with donation after
brain death (16% vs. 3%; Blok et al., 2016; Foley et al., 2011). Current
treatment options, such as endoscopic retrograde cholangiopan-
creatography and hepaticojejunostomy, often fail to restore biliary
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drainage and up to 65% of patients with ischemic cholangiopathy
after LT require retransplantation (Foley et al., 2011). Personalized
regenerative medicine strategies could prevent the need for re-
transplantation of the whole liver in case the donor liver is failing due
to aforementioned complications. Damaged extrahepatic bile duct
(EBD) can be replaced with functional tissue engineered constructs,
preferably built using the autologous cells. These strategies can po-
tentially relief the intense pressure on the already limited donor
organ pool.
The EBD is not merely a “simple tube” that transports cytotoxic
bile, as the EBD contains complex tortuous networks of peribiliary
glands (PBG) and blood vessels. The PBG can be found in‐ (in-
tramural) and outside (extramural) the wall of the EBD and play an
important role in maintaining homeostasis and bile duct regeneration
after injury (de Jong et al., 2018). The PBG are surrounded by small
blood vessels, which are also known as the peribiliary vascular plexus.
Recreating these small glandular and tortuous structures in vitro
with high precision is challenging. Therefore, the use of decellularized
extracellular matrix (ECM) could be an interesting alternative for
recreating EBD tissue in vitro, where the decellularized ECM func-
tions as a scaffold or the EBD (Crapo et al., 2011).
The decellularized scaffolds need to be repopulated with biliary
cells to restore the vital barrier function of the bile duct against the
cytotoxic bile. Human LGR5+ biliary organoids are an interesting
source of functional biliary cells, as organoids offer long‐term stable
in vitro expansion of cholangiocytes (Aloia et al., 2019; Huch et al.,
2015). This allows for the generation of large numbers of autologous
cells in vitro from relative small (liquid) biopsy samples.
The organoid cultures can be established from liver biopsies
(intrahepatic bile duct‐derived organoids [IDO]; Huch et al., 2015),
EBD tissue (extrahepatic bile duct‐derived organoids [EDO]; Rimland
et al., 2020; Sampaziotis et al., 2017), and bile samples (bile‐derived
organoids [BDO]; Soroka et al., 2018). The cells that give rise to these
biliary organoids are EPCAM positive and organoids from all three
sources maintain cholangiocyte‐specific markers (e.g., EPCAM, cyto-
keratin 7 [KRT‐7] or cytokeratin 19 [KRT‐19]) and functionality (Ai-
zarani et al., 2019; Aloia et al., 2019; Huch et al., 2015; Rimland et al.,
2020; Sampaziotis et al., 2017; Soroka et al., 2018). Furthermore,
relative small biopsies (0.5–1.0 g tissue or 1ml of bile) are adequate
to initiate cultures, which subsequently can yield millions of cells
(Schneeberger et al., 2020; Willemse et al., 2017). These character-
istics make the organoids ideal cell sources for the repopulation of
decellularized EBD scaffolds in an effort to create functional tissue
engineered bile ducts in vitro. However, whether biliary organoids
from all three sources are capable of efficient repopulation and re-
store the vital barrier function of the EBD, is yet to be determined.
Therefore, we aimed to develop an in vitro model for bile duct
tissue engineering in which the recellularization capacity and,
moreover, bile duct functionality after recellularization of the biliary
organoids collected from the three sources, can be assessed. We first
developed an efficient decellularization protocol for human EBD
tissue to obtain ductal ECM. Subsequently, IDO, EDO, and BDO were
expanded and used to recellularize the decellularized EBD scaffold.
Confluency was used as a measure for the seeding efficiency of the
epithelial monolayer. Furthermore, we analyzed expression of cho-
langiocyte markers and tested biliary function of the tissue en-
gineered constructs.
2 | METHODS
2.1 | Sample procurement
2.1.1 | Sample procurement for decellularization
Biopsies of healthy EBD tissue (N = 26) were collected during LT.
Before transplantation, the duct of the donor organ is shortened to
make the anastomosis with the recipients' bile duct. The removed
section (usually 3–10mm) was stored in Belzer UW cold storage
solution (UW; Bridge to Life) at 4°C. Four segments (3–5mm by
3–5mm) were cut from the biopsy. One segment was used for or-
ganoid initiation (see sample procurement for organoid initiation,
N = 5). The second segment was fixed in 4% paraformaldehyde (PFA;
Fresenius Kabi) for histological analysis. The two other segments
were snap frozen in liquid nitrogen and stored at −80°C for bio-
chemical analysis purposes. The remaining EBD tissue was stored in
1× phosphate‐buffered saline (PBS) at −20°C until decellularization.
The use of these biopsies for research purposes was approved by the
Medical Ethical Council or the Erasmus University Medical center
(MEC‐2014‐060) and patients gave their written informed consent.
Full length EBD tissue (average length: 3–5 cm, N = 8) was obtained
from human research livers. These livers were deemed unsuitable for
clinical transplant procedures in the EuroTransplant zone by all trans-
plant centers, due to a variety of reasons, such as steatosis and/or age
(N = 8). No organ retrieval was initiated for research purposes only. In all
cases, next of kin gave informed consent for research to Transplant
Coordinators of the Dutch Transplantation Society (NTS). The use of
research liver was approved by the Erasmus MC medical ethics com-
mittee (MEC‐2012‐090). After organ procurement, the liver was stored
in UW organ preservation fluid (Bridge to life) on ice and shipped to the
Erasmus MC, where the EBD was surgically removed from the liver.
Small biopsy samples were taken in a similar manner as previously
described, except for organoid initiation. The remaining EBD tissue was
placed in PBS and stored at −20°C.
2.1.2 | Sample procurement for organoid initiation
Biopsies of liver tissue (0.5–2 cm3; N = 5) and EBD tissue (N = 5) were
obtained for organoid initiation during LT at the Erasmus University
Medical Center Rotterdam from healthy donor tissue (N = 3) and
diseased explant tissue (N = 2; recurrent primary sclerosing cho-
langitis and Wilson's disease). Liver and EBD biopsies were donor or
patient paired. The use of these biopsies for research purposes was
approved by the Medical Ethical Council or the Erasmus University
Medical Center (MEC‐2014‐060) and written informed consent was
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given by the next of kin of the donor or by patients. Biopsies were
stored and transported in UW preservation fluid on ice.
Bile (1ml) was collected from patients (N =3) undergoing ERCP
procedures during treatment for primary sclerosing cholangitis, bile
leakage, or choledocholithiasis. The use of bile samples for research
purposes was approved by the Medical Ethical Council of the Erasmus
University Medical Center (MEC‐2016‐743). All patients gave written
informed consent. Samples were stored and transported on wet ice.
2.2 | Decellularization
The EBD was washed with dH2O until all traces of blood or bile were
removed from the EBD. The lumen of the full length EBD was flushed
using a blunt needle. Subsequently, the ductal tissue was incubated with
Trypsin‐EDTA (TE) (0.05%, Gibco) for 30min at 37°C on an orbital
shaker. TE was washed away with dH2O for 15min. Subsequently, the
EBD was placed in 50ml of 4% Triton‐X‐100 + 1%NH3 (T×100 solution)
on an orbital shaker at room temperature (RT). T×100 solution was
replaced every 30min until 10 cycles were reached. The EBD tissue was
placed in 50ml dH2O for 5min and dH2O was refreshed 10 times. The
decellularized EBD tissue was stored in 50ml dH2O at 4°C for 5–7 days
to remove traces of T×100. dH2O was refreshed every 1 or 2 days.
The decellularized duct was incubated with DNase solution
(Table S1) for 4 h at 37°C on an orbital shaker. Afterwards, the EBD
was placed in 50ml 0.9% saline solution, which was refreshed three
times. Biopsy samples were taken for histological and DNA analysis.
2.2.1 | Histology
PFA‐fixed samples were embedded in paraffin and sectioned at 4 µm.
Sections of before and after decellularization samples were stained
with hematoxylin and eosin (H&E) or 4′,6‐diamidino‐2‐phenylindole
(DAPI; Vectashield, Vectorlabs). H&E stained slides were imaged with
Zeiss Axiokop 20 microscope and captured with a Nikon DS‐U1
camera. DAPI stained slides were analyzed using EVOS microscope
(Thermo Fisher Scientific).
Immunohistochemistry (IHC) staining was performed on before
and after decellularization samples with Collagen Type I and Collagen
type IV (Table S4). Antigen retrieval was performed in citrate buffer
(pH = 6.0) at subboiling temperatures for 10min. Primary antibodies
were incubated over night at 4°C. Envision + system horseradish
peroxidase antirabbit secondary antibody (DAKO) was incubated at
RT for 60min, before staining with 3'‐diaminobenzidine and and
counterstaining with hematoxylin.
2.2.2 | Scanning electron microscopy
Small PFA‐fixed biopsies (before and after decellularization, N = 2)
were dehydrated with ethanol and hexamethyldisilazane (Sigma)
series before gold sputtering (15 µm) using a Quorum Q300T D
sputtering device (Quorumtech). Biopsies were imaged with a JSM‐
7500F field emission electron microscope (JEOL).
2.2.3 | Biochemical analysis
The wet weight of the samples was weighed before performing
analysis.
DNA was isolated using a QIAamp DNA mini Kit (Qiagen) fol-
lowing the manufacturer's protocol. DNA content was measured
using a NanoDrop spectrophotometer (Thermo Fisher Scientific;
N = 11) and corrected for the corresponding wet weight of the
measured sample (ng DNA/mg wet weight tissue). The quality and
length of DNA base pairs (BP) was measured using a 2100 BioAna-
lyzer (Agilent technologies) using a DNA‐1000 kit (Agilent
Technologies).
Total collagen content of the samples was determined using a
Total Collagen Kit (Quickzyme Biosciences, N = 9). Collagen content
was measured in a clear 96‐well plate at 570 nm using an Omega
POLARstar Microplate reader (BMG labtech). The content was cor-
rected for the wet weight of the corresponding samples (µg Collagen/
mg wet weight tissue).
Sulfated glycosaminoglycan (sGAG) was determined using a
Blyscan glycosaminoglycan assay (Biocolor; N = 15). Samples were
digested in a Papain (Sigma) solution (10mg/ml) at 65°C for 8 h.
sGAG was isolated from the sample digest according the manu-
facturers protocol. The sGAG content was measured by absorbance
measurements (680 nm) in a clear 96‐well plate using a model 680
XR microplate reader (Bio‐Rad).
2.3 | Recellularization
2.3.1 | Initiation tissue derived organoids (IDO
and EDO)
Organoid initiation was similar as previously described (IDO; Huch
et al., 2015; EDO; Rimland et al., 2020). See Figure 1b for a
schematic overview of organoid initiation and the section “Sample
procurement for organoid initiation” for more details on tissue
procurement. In short, biopsies were minced, digested in 2.5 mg/ml
collagenase type A (Sigma) for 20 min at 37°C. The cell suspension
was strained (70 µm cell strainer) and washed in cold Advanced
DMEM/F12 (Adv+, Table S2). After centrifugation (1500RPM,
5 min, 4°C) the remaining cell pellet was suspended in reduced
growth factor basement membrane matrix (BME, Cultrex) solution
(70% BME, 30% cold Adv+). The mixture was plated in 25 µl dro-
plets in a 48‐well suspension culture plate (Greiner). The BME
solidified at 37°C for 30–45 min before startup medium (SM,
Table S3) was added. After 3 days SM was replaced with expansion
medium (EM, Table S3).
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2.3.2 | Initiation bile‐derived organoids
The obtained bile was suspended in 8ml cold Adv+, centrifuged
(1500RPM, 5min, 4°C) and the supernatant was removed. This
procedure was repeated once. The remaining cell pellet was sus-
pended in 3ml cold Adv+, strained (100 µm cell strainer) and cen-
trifuged. The cell pellet was suspended in 70% BME solution and cells
were treated similar to IDO and EDO.
2.3.3 | Culturing organoids
EM was refreshed of all three types of organoids every 3 to 4 days.
Organoids were split in 1:4 to 1:6 ratios every 7 to 10 days de-
pending on proliferation rate of the cells by mechanical dissociation
and replating of organoids fragments in fresh BME.
2.3.4 | Preparation of the ECM
Full length decellularized EBD was cut open along the longitudinal
axis (Figure 1a). Circular discs (Ø 3mm) were cut using disposable
dermal biopsy punches (Stiefel). The discs were collected in 50ml 1×
PBS and washed in PBS three times. This was repeated with Adv+
and with Adv+ supplements with 10× concentration Pen/Strep and
primocin. The discs were incubated overnight at 37°C. The discs were
washed in Adv+. The ECM was placed in the middle of a 48‐well
45min before addition of cells. Residual adv+ was removed from the
surface and side of the discs.
2.3.5 | Recellularization experiments
Organoids were harvested by removing the BME droplets from the
wells using cold adv+, as previously described (see Figure 1c for a
schematic overview). In general, a full BME droplet (average yield:
6.0 × 104 cells, SD:±2.0 × 104 cells per dome) was used per ECM disc.
After removal of BME from the cell pellet, 1 ml TE was added. The
suspension was incubated at 37°C until organoid fragments were
dissociated into a single cell suspension. The cells were counted using
disposable cell counting chambers (Kova). About 10 µl cell suspension
was added to the center of the ECM discs.
The samples were incubated at 37°C for 2 h before 500 µl EM
supplemented with 10 µM Y27632 was added to the wells. EM
+Y27632 was replaced with EM after 3 days and medium was
refreshed every 3 or 4 days. The ECM‐cell construct was kept in
culture for up to 21 days. Organoid cultures in BME served as a
control.
After 21 days experiments were terminated. About 4–6 samples
were fixed in 4% PFA for 20min. These samples were used for his-
tological analysis or whole mount staining. These 4–6 samples were
lyzed in 700ul Qiazol lysis reagent (Qiagen) and stored at −80°C for
quantitative polymerase chain reaction (qPCR) analysis.
2.3.6 | Ussing chamber experiments
Larger segments (W: 1 cm, L: 2 cm) of ECM were cut from the EBD
using a scalpel. The recellularization procedure was similar to the
circular discs recellularization, however, the cell number was in-
creased five‐fold (see Figure 1d for a schematic overview). About
5×10 µl cell suspension droplets were used for each segment. Fur-
thermore, EM was refreshed every 1–2 days. After 21 days the
segment was cut in two equal sized parts. Each part was placed in an
Ussing slider (P2303A, area: 0.10 cm2, Physiologic Instruments,
Figure S2) and subsequently placed in the Ussing chamber (Physiologic
Instruments). Decellularized ECM was used as a control for the
Ussing chamber experiments. The Ussing chambers were filled with
Meyler's medium (Table S7) supplemented with 10mM glucose. The
Ussing chambers were kept at 37°C and a 95% O2 5% CO2 gas
mixture was bubbled through the chambers. A VCC MC8 voltage
clamp module (Physiologic Instruments) was used to clamp the
potential difference at 0 mV. The short circuit current (Isc) was
recorded using Acquire and Analyze 2.3 software (Physiologic
Instruments). Trans epithelial electrical resistance (TEER) measurements
was measured by applying three 5V spikes. The resistance was
calculated according to Ohm's law
R V I= / (1)
The resistance of the recellularized constructs was calculated by
subtracting measured resistance value of decellularized ECM
R R Rorganoids constructs decellularized ECM= − (2)
F IGURE 1 Graphical representation of human EBD decellularization and recellularization procedures. (a) Decellularization of EBD tissue
was performed with T×100 solution. After decellularization the full length EBD was cut open along the longitudinal axis and circular discs
(Ø3mm) are punched using a dermal biopsy punch. (b) Organoids were initiated from three different sources; liver tissue (IDO), EBD tissue
(EDO), and bile samples (BDO). The cells obtained from these sources were embedded in BME and cultured as per normal protocol.
(c) Recellularization experiments start with dissociation of the organoids. A suspension of single cells (10 µl) was added to the ECM and kept in
culture for up to 21 days. (d) Recellularization experiments for Ussing Chamber were performed in a similar manner as the normal
recellularization experiments. After a 21‐day culture period, the recellularized construct was carefully placed inside the Ussing chamber setup,
followed TEER and ion‐channel activity measurements in Ussing chambers. BDO, bile‐derived organoids; BME, basement membrane matrix;
EBD, extrahepatic bile duct; ECM, extracellular matrix; EDO, extrahepatic bile duct‐derived organoids; IDO, intrahepatic bile duct‐derived
organoids; TEER, trans epithelial electrical resistance [Color figure can be viewed at wileyonlinelibrary.com]
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Rorganoids was subsequently corrected for the surface area
(A = 0.10 cm2) of the Ussing slide
TEER R Aorganoids tissueslide= ⋅ (3)
Subsequently, ion‐channel activity was measured. CFTR‐
dependent anion secretion was activated by adding forskolin
(10 µM) to the basolateral side of the constructs and inhibited by
addition of GlyH‐101 (20 µM, apical). The calcium activated
chloride channels (CaCC) were stimulated by addition of UTP
(50 µM, apical).
2.3.7 | Immunohistochemistry of organoids
Organoids were cultured in BME, fixed in 4% PFA and embedded
in paraffin. Subsequently, IHC staining was performed as
described previously for the IHC procedure in the histology
Section (2.2.1). The primary antibodies (Cytokeratin 7 (KRT‐7)
and cytokeratin 19 (KRT‐19; Table S4) were incubated overnight
at 4°C. The secondary antibody (Table S5) was incubated at RT
for 60 min.
Whole mount confocal imaging was performed on 4% PFA fixed
recellularized scaffolds. Recellularized ECM samples were permea-
bilized with 0.1% Triton‐X‐100 in 1× PBS for 20min. The samples
were blocked in 5% serum in 1× PBS for 60min. The primary anti-
bodies (see Table S4) were incubated overnight at 4°C. The sec-
ondary antibody (Table S5) was incubated at RT for 60min. KRT‐7
and KRT‐19 samples were additionally stained with Phalloidin Alexa
Fluor 488 (Thermo Fisher Scientific). All samples were stained with
DNA‐staining DAPI. Samples were imaged using a Leica ×20 water
dipping lens on Leica DM6000 CFS microscope with a LEICA TCS
SP5 II confocal system. Images were processed and analyzed using
ImageJ.
2.3.8 | qPCR gene expression analysis
Qiazol lyzed samples were homogenized using a TissueRuptor
(Qiagen). Messenger RNA (mRNA) isolation was performed with
the miRNeasy kit according to the manufacturers' protocol. RNA
content was measured using a Nanodrop and complementary DNA
(500 ng) was prepared using 5× PrimeScript RT Master Mix and a
2720 thermal cycler (Applied Biosystems). qPCR was performed
according to standard procedures with SYBR select master mix for
SFX (Applied Biosystems) on a StepOnePlus real time PCR System
(Applied Biosystems). All the tested primer sets are listed in
Table S6.
GAPDH, B2M, and HPRT were used as reference genes. The
geometrical average of the three housekeeping genes was used as
previously described (Vandesompele et al., 2002) for determining the
dCt of the genes.
2.4 | Data analysis
Analysis of data was performed with Prism (version 8.0, Graphpad
Software). Data from DNA, RNA, total collagen, sGAG content, and
Nuclei per mm2 is displayed as mean ± standard deviation (SD).
Nonpaired t‐test were performed to analyze means. Analysis of
variance on ranks was performed for the quantified nuclei data.
qPCR data is displayed as 2−dCt in “before–after” graphs, were “be-
fore” represents the BME controls and “after” the recellularized
constructs of the same donor/patient. Wilcoxon matched pairs tests
were performed on qPCR data.
3 | RESULTS
All EBD samples showed severe signs of denudation before decel-
lularization, as no confluent layers of cholangiocytes could be found
(Figures 2b and 2d). This was likely the result of ischemia. Due to the
denudation, no cholangiocyte RNA of adequate quality could be
obtained from fresh EBD tissue. During decellularization, the
bile ducts underwent a slight change in color from yellow/white to
white (Figure 2a). The decellularization procedure did not affect the
dimensions of the EBD, as no shrinking or expansion was witnessed
(Figures 2a and S1). However, loose connective tissue fibers sur-
rounding the bile ducts (Figures 2a and S1), detached as a result of
gentle agitation on the rocker and was washed away during re-
placement of T×100 solution. This connective tissue did not contain
muscle, extramural PBG or blood vessel structures. Full length EBDs
were cut open along the longitudinal axis after the decellularization
procedure was completed and showed typical “golf ball‐like” surface
macroscopically (Figure 2a). The decellularization procedure did not
affect the macroscopic architecture of the luminal side of the duct.
All cells were efficiently removed during the decellularization
procedure (Figure 2b) and no dsDNA (Figure 2c) was detected in
the decellularized EBD. DNA quantification (Figure 2g) showed a
significant (p < .001) decrease in DNA content to 11.9 ng DNA
(SD:±9.2 ng). No fragment of dsDNA could be detected by the
BioAnalyzer after decellularization (Figure S1), confirming complete
decellularization. The fibrous ultrastructure of the ECM remained
intact and was not affected by the procedure as shown by Scanning
electron microscopy (SEM; Figure 2d). IHC staining of the decellular-
ized bile ducts for Collagen I and IV showed that these proteins remain
present (Figure 2e,f). The total collagen content did not differ sig-
nificantly (p = .69) before (64.9 µg/mg wet tissue, SD:±21.0 µg/mg) and
after decellularization (57.6 µg/mg wet ECM, SD:±12.9 µg/mg). The
sGAG content decreased significantly (p < .001) after decellularization
(before: 16.4 µg/mg wet tissue, SD: ±6.8 µg/mg; after: 1.4 µg/mg wet
ECM, SD: ±1.1 µg/mg), which could be due to the detachment and
subsequent removal of connective tissue on the outside of the ductal
tissue, however, this was not further determined.
Organoids from all three ductal sources proliferated well, were
spherical in shape (Figure S2) and were comparable with organoids as
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previously described by other publications (Huch et al., 2015;
Rimland et al., 2020; Sampaziotis et al., 2017; Soroka et al., 2018).
The organoids were KRT‐7 and KRT‐19 positive (Figure S2). Differences
in proliferation patterns were noticed, however, these were attributed
to donor‐donor variances, as patient/donor paired organoids showed
similar characteristics (data not shown). Similar findings were also
mentioned by other publications (Huch et al., 2015). Furthermore, no
significant differences were noted between organoids derived from
healthy donor or liver patients, as all organoids were similar in size,
shape or proliferation patterns.
Bright field microscopic evaluation of the recellularization ex-
periments was limited as a result of the density of the ECM. How-
ever, viable cells surrounding the scaffolds were detected 24 h after
initiating the recellularization with organoids from all three sources
(Figure 3a). After 7–10 days transparent rim was seen surrounding
the edge of the ECM disc in EDO and BDO recellularized samples. In
IDO samples, this rim was inconsistent and did not fully cover the
entire disc. Cyst‐like structures were seen inside the rim (Figure 4a).
Between Day 15 and 18 these cystic structures disappeared in EDO
and BDO samples and an uninterrupted rim encapsulated the edges
of these samples after 21 days (Figure 3a). Cells with columnar
phenotypes surrounded the ductal ECM (Figure 3c). This was not
consistent with IDO recellularized samples, which had either cells
with a flattened phenotypes or cystic structures after 21 days
(Figures 3b and 3d).
Whole mount confocal analysis with F‐actin staining showed that
confluent monolayers covered the entire surface of ECM discs re-
cellularized with EDO and BDO (Figure 3g,h). “Honey comb”‐like
structure were visible at ×40 magnification (Figure S2), showing that
F‐actin is located at the edges of the cell membranes, where the cells
attach to each other. ECM repopulated with IDO did not reveal si-
milar patterns. Three out of five samples from this source failed to
form a confluent layer on the entire surface of the ductal ECM
(Figures 3i and S2). The two other samples lacked “honey comb”‐ like
structures. The “success rate” as determined by the number of
samples which were fully repopulated upon examination with whole
mount confocal imaging is 40% for IDO (Figure 3j), whereas this rate
was 100% for EDO and BDO. Quantification of nuclei per set area
(Figure S2 contains representative images for all conditions) revealed
that IDO repopulated samples contain significantly (p < .01) less nu-
clei per mm2 (17.1 nuclei per mm2, SD:±6.3) than EDO (24.9 nuclei
per mm2, SD:±4.2) and BDO (25.0 nuclei per mm2, SD:±4.6). The
difference between completely repopulated IDO samples (confluent,
20.5 nuclei per mm2, SD:±5.2) with the partially repopulated IDO
samples (not confluent, 12.9 nuclei per mm2, SD:±4.8) was also sig-
nificant (p < .01, Figure S2). Even after full repopulation with IDO, the
number of nuclei per set area was lower when compared with sam-
ples repopulated with EDO and BDO, however, this difference is not
significant.
Expression of cholangiocyte marker cytokeratin‐7 (KRT‐7) dif-
fered between EDO, BDO and IDO repopulated ECM (Figure 4a–c),
as KRT‐7 expression was lower in IDO samples compared with EDO
and BDO. Cholangiocyte marker cytokeratin‐19 (KRT‐19) expression
was similar for all repopulated ECM samples (Figure 4d–f). Protein
expression of Zone Occludens‐1 (ZO‐1) was also seen in ECM sam-
ples recellularized with organoids from all three types, however,
expression was seen in different patterns (Figure 5g–i). In EDO and
BDO samples, ZO‐1 was located in between cells, showing that tight
junctions formed between individual cells (Figure 4g,h). The XZ‐plane
revealed that ZO‐1 expression was found at the luminal side,
whereas nuclei are located at the basolateral side of the cells. This
indicates cholangiocyte‐like polarization of the cells on EDO and
BDO recellularized samples. Again, IDO showed a different pattern,
as these cells lacked the “honey comb”‐like structured, had flattened
phenotypes and no polarization was witnessed (Figure 4i)
Specific gene expression analysis showed a decrease in expres-
sion of LGR5 (Wnt target gene) after recellularization when com-
pared with matched BME controls (Figure 5). IDO showed an
approximate four‐fold decrease, whereas EDO had a 6.5‐fold and
BDO a 10‐fold decrease after recellularization. SOX‐9 (biliary pro-
genitor marker) expression of BDO samples (both BME controls and
recellularized samples) was higher compared with SOX‐9 expression
of EDO and IDO samples. Focusing on BDO samples only, the SOX‐9
expression decreased threefold after recellularization when com-
pared with matched BME controls.
Expression of NOTCH‐2 was increased (approximately EDO: 3.5‐
fold, BDO: 6.1 fold, and IDO: 3.1‐fold) after recellularization, in-
dicating differentiation towards cholangiocytes. Interestingly, a
F IGURE 2 Decellularization of human extrahepatic bile duct tissue is feasible. (a) Macroscopic images of before and after decellularization.
The ostia of the PBG are visible (outtake). (b) Before and after decellularization images of H&E stained paraffin slides showing the surface of the
EBD (left) and intramural PBG (right). Scale bars represent: 200 µm. (c) DAPI staining revealed that after decellularization no visible dsDNA is
present in the decellularized ECM on the surface of the EBD or in the PBGS. Scale bars represent: 200 µm. (d) Scanning electron microscopy
images before decellularization shows the expected denudation of the extrahepatic bile duct as only a few cells can be seen at two different
magnifications from the same sample. After decellularization all cells were removed and the ultrastructure of the ECM remains intact as is
shown by two different magnifications from the same sample. Scale bars represent 200 µm left side, 10 µm top right, 1 µm bottom right.
(e) Collagen Type I remains present after decellularization. Scale bars represent: 200 µm. (f) Collagen type IV remains present in the PBG after
decellularization. Scale bar represents: 200 µm. (g) Results from the biochemical analyses. DNA drops significantly (***p < .001) after
decellularization to 11.9 ng DNA (SD ± 9.2 ng DNA). Total collagen content does not differ significantly (N = 9). sGAG content decreases
significantly (***p < .001) to 1.4 µg sGAG/mg ECM (SD± 1.0 µg sGAG; N = 15). DAPI, 4′,6‐diamidino‐2‐phenylindole; EBD, extrahepatic bile duct;
ECM, extracellular matrix; H&E, hematoxylin and eosin; PBG, peribiliary glands; sGAG, sulfated glycosaminoglycan [Color figure can be viewed
at wileyonlinelibrary.com]
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decrease in KRT‐7 (approximately EDO: 8‐fold, BDO: 2.3 fold, and
IDO: 1.6 fold decrease) and KRT‐19 (approximately EDO: 2.5‐fold,
BDO: 2‐fold, and IDO: 1.7‐fold decrease) was measured, whereas
KRT‐7 and KRT‐19 staining showed that on protein level these
proteins are still expressed. Recently, it was shown that there is no
significant differential gene expression of KRT‐7 and KRT‐19 be-
tween primary extrahepatic cholangiocytes and EDO (Rimland et al.,
2020). Expression of mature cholangiocyte markers MUC‐1, TFF‐1,
TFF‐2, EPCAM, TROP‐2, and HNF‐1β remained stable.
KI‐67 expression, as indicator for cell proliferation, decreased
when recellularized with EDO and BDO, whereas in some of the IDO
samples this was inconclusive. The IDO samples, which reached
confluency had a decrease in KI‐67 expression (1.6‐fold, 33‐fold, and
50‐fold), whereas nonconfluent IDO samples had an increase (4.4 and
1.2 fold) in expression when compared with matched BME controls.
In all cases, an increase in Vimentin expression was measured after
recellularization (EDO: 3.8‐fold, BDO: 1.6‐fold, and IDO: 9.7‐fold
increase) indicating that cells were undergoing epithelial‐to‐
mesenchymal transition.
Expression of the cholangiocyte‐specific transporter and channel
genes CFTR, SLC‐4a2, and SLC10a2 (ASBT) was also detected
(Figure S3) suggesting that the cells could be capable of performing
anion and bile salt transport functions. Recellularization on ECM
discs did not affect expression of hepatocyte markers Albumin,
CYP‐3a4, ABCB11 (BSEP), and HNF‐4α (Figure S3). No apparent
hierarchical clustering could be found between recellularized
samples or organoids from the same patients in BME. Similarly, no
clustering could be found between organoids derived from healthy
donors or patients (data not shown).
Whole mount confocal analysis of ductal ECM recellularized with
EDO or BDO after staining with acetylated α‐tubulin revealed pre-
sence of primary cilia in these samples (Figure 6a). The XZ‐plane
revealed that cilia can be found on the apical side of the cells similar
to the in vivo situation (Figure 6a, XZ plane). No acetylated α‐tubulin
was detected in IDO‐repopulated scaffolds.
IDO recellularized samples were not assessed for functionality
testing, as these organoids failed to fully repopulate the ductal ECM.
The Ussing chamber experiments required larger ECM samples (L:
2 cm, W: 1 cm) and therefore the amount of cells used was increased
fivefold (approx. 3.0 × 105 cells per segment). Recellularization pat-
terns were similar to those of the circular ductal ECM. However, due
to the increased number of cells, EM had to be refreshed more often.
During the last 7 days of the 21‐day period, medium was refreshed
every 24 h.
Recellularized constructs had TEER of 17.8Ω·cm2 (SD:±1.4
Ω·cm2) and 21.1Ω·cm2 (SD:±4.7Ω·cm2) for ductal ECM recellularized
with EDO and BDO, respectively (Figure 6e). No fresh tissue was
used as a control, due to the severity of denudation of EBD tissue.
CFTR‐channel activity was induced by addition of forskolin (cAMP
agonist). The segments repopulated with EDO showed a relatively
small response (Figure 6f), whereas no change in Isc was detected for
BDO samples (Figure 6g). Both the EDO and BDO recellularized
constructs responded to GlyH‐101 induced blockage of the CFTR‐
channel with a reduction in anion secretion. This indicates that CFTR‐
channels in the BDO recellularized ECM constructs were already
active, presumably caused by the presence of forskolin in EM. Sub-
sequent activation of CaCC with the purinergic Ca2+ agonist UTP
caused a transient increase in Isc in both samples. UTP was added to
the luminal side of the constructs, thus the response indicates proper
polarization of the epithelial cell layer with both CFTR and CaCC
channels localized at the apical cell surface. Decellularized ECM was
taken along as a negative control and did not respond to any of the
additions (Figure S2).
4 | DISCUSSION
The ability to engineer personalized functional EBD constructs in
vitro may have considerable impact on the management of biliary
complications after LT. Here, we demonstrated efficient
F IGURE 3 EDO and BDO can fully repopulate the luminal surface of ductal ECM. (a) Decellularized ECM were not transparent. Only cells
surrounding the edges of the scaffold can be monitored. After 24 h cells can be found surrounding the ECM of EDO and BDO recellularized
samples. After 7 days a semitransparent rim appeared, which contained cystic structures (white arrow). After 21 days no cystic structures could
be detected (scale bars: 200 µm). (b) IDO were less efficient in recellularization of ductal ECM, as they formed thin edges surrounding the ECM.
IDO showed either a cystic‐phenotype or flattened phenotype after 21‐days (scale bars: 200 µm). (c) EDO and BDO that encapsulated the
luminal surface of the ECM had a columnar phenotype, where the nucleus was located towards the apical side of the ECM. (d) Cells were found
inside the lumen of the ostia of the PBG. (e) IDO lack the columnar phenotype. Cells are flattened in shape. (f) In some cases, where IDO fail to
recellularize the ductal ECM, cystic structures are seen after 21 days. Scale bars (c–f) 200 µm. (g–i) F‐actin staining on whole mounted samples.
(g and h) EDO and BDO are capable of forming confluent layers on the luminal surface of the ductal ECM. Ostia of PBG (h) are also repopulated.
(i) IDO expresses a different phenotype, as recellularization was not completed. Scale bar GHI: 200 µm. (j) The “success rate” as determined by
the percentage of completely repopulated samples. For EDO and BDO the success rate was 100% as organoids from each donor or patient
formed confluent layers (N = 5 EDO and N = 3 BDO). For IDO this percentage was 40%, as organoids from only two donors or patients were
capable of forming confluent layers. The other three donor or patient IDO formed flattened layers with holes. (k) The amount of nuclei counted
per mm2. EDO and BDO have 24.9 nuclei (SD:±4.2) and 25.0 nuclei (SD:±4.6) per mm2 respectively. The nuclear density of IDO differs
significantly with EDO and BDO repopulated samples (**p < .01). IDO repopulated samples contained 17.1 nuclei per mm2 (SD:±6.3). Success
rate (j) and nuclear density (k) were determined by examination and analysis of five whole mount confocal Z‐stacks of each source (N = 4 EDO
and IDO, N = 3 BDO). BDO, bile‐derived organoids; ECM, extracellular matrix; EDO, extrahepatic bile duct‐derived organoids; IDO, intrahepatic
bile duct‐derived organoids; PBG, peribiliary glands [Color figure can be viewed at wileyonlinelibrary.com]
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decellularization of human EBD tissue and showed preservation of
the ultrastructure of the EBD. Subsequent successful recellulariza-
tion with cells derived from EDO and BDO, but not from IDO, was
shown. The recellularized ductal ECM expressed mature cholangio-
cyte markers (such as KRT‐7, KRT‐19, NOTCH‐2, TFF‐1, and TFF‐2)
and demonstrated cholangiocyte‐specific ion‐channel functionality.
This provides proof of principle that in the near future, patient‐
specific, transplantable and functional EBD tissue constructs could be
engineered in vitro, which can be used to replace or repair damaged
EBD tissue in vivo.
The use of decellularization strategies for ductal tissue en-
gineering purposes has previously shown successful in animal models.
F IGURE 4 Organoids derived from EBD tissue or bile samples can be used to repopulate the apical surface of ductal ECM. (a–c) EDO and
BDO express cytokeratin‐7 (KRT‐7), whereas IDO showed lower expression of KRT‐7. (d–f) cytokeratin‐19 (KRT‐19) expression was similar
between EDO, BDO, and IDO. (k–m) Zone Occludens‐1 (ZO‐1) expression showed that EDO and BDO had a “honey comb”‐like phenotype. ZO1
was located on the luminal side (XZ plane), whereas nuclei were located at the basolateral side, indicating cholangiocyte‐like polarization of the
cells. IDO recellularized samples had a flattened phenotype and no polarization of ZO‐1 was detected. Scale bars: (a–f) = 200 µm and
(g–i) = 100 µm. BDO, bile‐derived organoids; ECM, extracellular matrix; EDO, extrahepatic bile duct‐derived organoids [Color figure can be
viewed at wileyonlinelibrary.com]
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Cheng et al. (2016) successfully transplanted a decellularized ureter,
splinted by a silicone stent or a T‐tube, in guinea pigs. In parallel,
Struecker et al. (2016) transplanted porcine abdominal aorta, which
was recellularized with autologous cholangiocytes, in a porcine
model. However, ureter or aorta ECM does not resemble the archi-
tecture of human EBD as these structures are lacking the complex
PBG architecture.
Decellularization of human EBD tissue was efficient and did not
damage the architecture of the ECM. The loss of connective tissue
surrounding the EBD could account for the decrease in sGAG con-
tent, although this was not further quantified. The decrease of sGAG
did not appear to impact the formation of confluent cell‐layers, as
EDO and BDO successfully repopulated the surface of the ductal
ECM. Further analysis of the repopulated ductal ECM showed
F IGURE 5 mRNA expression data before (BME) and after recellularization (Recell) on top of the ductal ECM of matched organoids from
different origins. Cholangiocyte differentiation or stem cell markers are shown in panel (a). Cholangiocyte‐specific genes are shown in panel (b).
Proliferation (KI‐67) and epithelial‐to‐mesenchymal transition marker (Vimentin) are displayed in panel (c). The RT‐qPCR data is displayed as
2−dCt. Wilcoxon signed rank test did not reveal any significant differences between the marched BME and recellularized samples. BME,
basement membrane matrix; ECM, extracellular matrix; mRNA, messenger RNA; RT‐qPCR quantitative reverse‐transcription polymerase chain
reaction
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cholangiocyte‐like cells, which expressed cholangiocyte markers on
RNA and protein level. Furthermore, they had a functional barrier
allowing measurements of vectoral transport of anions through
cholangiocyte‐specific ion‐channels (CFTR and CaCC). These re-
sponses could not be compared with healthy and viable EBD‐tissue,
as all EBD tissue obtained from LT procedures showed extensive
denudation of the cholangiocyte monolayer and did not possess a
functional barrier anymore. However, the responses measured were
in similar order of magnitude as the responses measured for human
gall bladder epithelium (Chinet et al., 1999).
Although IDO expressed similar cholangiocyte markers, they
were less successful in fully repopulating the bile duct ECM. This
difference in recellularization efficiency could be explained by re-
gional differences in human biliary tissues. The extrahepatic and in-
trahepatic bile ducts are of different embryonic origin, arising from
different progenitors during embryonic development (Zong & Stan-
ger, 2011). This results in transcriptional differences between EBD or
IBD cholangiocytes. Rimland et al. (2020) recently demonstrated that
these differences are retained in vitro in the organoids initiated from
different sources. Therefore, organoids of extrahepatic origin could
be best suited to repopulate the decellularized ECM of the EBD. IDO,
on the other hand, could potentially be more useful for repopulation
of decellularized IBD (Willemse et al., 2020), which is vital for
creating for functional liver tissue constructs in vitro.
Biliary organoids are an alternative source of primary cho-
langiocytes of which expansion in vitro is challenging (Tabibian et al.,
2014). The organoids were obtained from healthy donors or from
patient material (see Section 2 “Sample procurement for organoid in-
itiation” for indications). No significant differences between healthy
or “diseased” organoids were witnessed in manner of proliferation or
mRNA expression profiles, and there was no difference in re-
cellularization capacity. This indicates that autologous cells from
patients could be used for personalized regenerative medicine pur-
poses. BDO can obtained through less invasive ERCP procedures,
making BDO more ideal for personalized purposes. EDO from donors
could be used as an alternative when patient‐derived cells are not
available.
Biliary LGR5+ organoids offer specific advantages when used in
tissue engineering over other cell sources, such as induced plur-
ipotent stem cells (iPSC), mostly because organoids are less prone to
(epi)genetic variation (Huch et al., 2015; Rebuzzini et al., 2016).
Furthermore, iPSC require extensive reprogramming and
F IGURE 6 Functional bile duct constructs can be created in vitro using EDO or BDO. (a–d) Acetylated α‐tubulin staining shows the presence
of cilia in EDO and BDO recellularized samples. Scale bars: (a) 100 µm, (b–d): 50 µm. (e) TEER measurements show an increase in resistance
compared to decellularized ECM (N = 3 measurements per sample). (f) and (g): Ussing chamber experiments showing short circuit current (Isc)
changes upon consecutive addition of Forskolin (a cAMP agonist), GlyH‐101 (CFTR inhibitor), and UTP (Ca2+ agonist and CaCC activator) of
EDO recellularized ECM (f, N = 2) and BDO recellularized ECM (g, N = 2). After addition of Forskolin a small response in EDO samples was
recorded, but not in the BDO samples. GlyH‐101 successfully blocked CFTR‐channel activity in both samples, as a decrease Isc was recorded.
Addition of 50 µM UTP showed an increase in current for both samples indicating the presence of CaCC. BDO, bile‐derived organoids; CaCC,
calcium activated chloride channels; ECM, extracellular matrix; EDO, extrahepatic bile duct‐derived organoids; TEER, trans epithelial electrical
resistance [Color figure can be viewed at wileyonlinelibrary.com]
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differentiation protocols, whereas no differentiation protocols were
needed to create functional EBD constructs in vitro. The organoids
already express mature cholangiocyte markers TFF‐1, TFF‐2, and
MUC‐1 (MacParland et al., 2018; Segal et al., 2019). In addition,
extrahepatic organoids have shown to be efficiently used for ductal
tissue engineering purposes in vivo. Sampaziotis et al. (2017) de-
monstrated that extrahepatic organoids can successfully replace
extrahepatic bile duct in mice, albeit that the culture medium for
initiating and expanding the organoids differed from ours. Further-
more, they used an artificial collagen scaffold, which lacks tissue‐
specific architecture, such as PGB. Therefore, the use of collagen
scaffolds might be less optimal for long‐term homeostasis of the
engineered bile duct. An advantage of applying decellularization
strategies is that these architectural features do remain present after
decellularization of EBD.
However, several “hurdles” have to be taken before decel-
lularized and repopulated human ductal ECM can be clinically
used. First and foremost, a translational step from the small two‐
dimensional sections towards three‐dimensional (3D) tubular
structures has to be made. This involves increasing the surface
area that needs to be recellularized and an increase in the number
of cells. Subsequently, there will be an increase in oxygen and
nutrient consumption and it is likely that this translation requires
more complex culture systems, such as perfusion‐based bior-
eactors. Furthermore, maintaining viability of cholangiocytes after
transplantation would require the development of a blood vessel
network. Struecker et al. (2016) showed feasibility of transplanting
a bile duct construct solely with cholangiocytes in a large animal
model without forming blood vessels (before transplantation). This
could suggest that a preformed blood vessel network is not
required, as formation of blood vessel after implantation appeared
to be adequate. However, this study was performed in healthy
animals and more research is required whether this holds true for
patients with defective EBD tissue.
Another important issue is the use of non GMP‐compliant
basement membrane extracts, such as Matrigel or Cultrex BME, for
the initiation and expansion of organoids. These extracts are created
from mouse tumor tissue (Benton et al., 2014; Hughes et al., 2010)
and are limiting the clinical applications of the organoids and sub-
sequently of recellularized EBD constructs (Willemse et al., 2017). To
overcome this “hurdle,” clinically relevant and well‐defined culture
substrates are required. Alternative candidates have already been
investigated for organoids cultures (Giobbe et al., 2019; Gjorevski
et al., 2016; Krüger et al., 2020).
5 | CONCLUSION
Here, we show successful recellularization of decellularized EBD
tissue using ductal organoids. Both EDO and BDO are promising cell
sources to be used in personalized biliary tissue engineering, as they
maintain cholangiocyte‐marker expression, showed restored barrier
function and possessed cholangiocyte‐specific ion‐channel activity. In
this study, we identified BDO as the most suitable candidate for
future use in building functional 3D tubular EBD constructs. This is
mostly due to easy access and minimally invasive collection of bile
from patients.
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